Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCarrera Álvarez, Cristina-
dc.contributor.authorPuig Butillé, Joan Anton-
dc.contributor.authorTell Martí, Gemma-
dc.contributor.authorGarcía Herrera, Adriana-
dc.contributor.authorBadenas Orquin, Celia-
dc.contributor.authorAlós i Hernández, Llúcia-
dc.contributor.authorPuig i Sardà, Susana-
dc.contributor.authorMalvehy, J. (Josep)-
dc.description.abstractIMPORTANCE: BRAF inhibitors have become the standard of care in metastatic BRAF-mutant melanomas. Compared with chemotherapies, BRAF inhibitors improve overall and disease-free survival and speed the recovery of symptomatic patients with metastatic disease. The most worrisome finding is the possible development of resistance to new malignant tumors. OBSERVATIONS: A patient in her 30s developed massive BRAFV600E melanoma metastasis during her 30th week of pregnancy. After emergency cesarean delivery, oral dabrafenib treatment was initiated, and a partial radiologic response was confirmed within 1 month. At dermatologic digital follow-up aided by confocal microscopy 8 weeks after initiation of dabrafenib treatment, 4 melanomas were detected. Unfortunately, within the next month, the melanoma rapidly progressed. The 4 new melanomas were wild-type BRAFmelanomas, whereas the new metastasis carried a different BRAF mutation (S467L). CONCLUSIONS AND RELEVANCE: Cutaneous malignant tumors are the most frequent adverse events of BRAF inhibitors; therefore, strict dermatologic surveillance in a referral center aided by digital follow-up is mandatory, especially when multiple nevi are present and these drugs are used in an adjuvant setting. In view of our findings, the pathogenesis of the development of new melanomas seems to be different from therapy resistance. Whether paradoxical RAF activation could explain these BRAF wild-type secondary malignant tumors is still unknown.-
dc.format.extent5 p.-
dc.publisherAmerican Medical Association-
dc.relation.isformatofReproducció del document publicat a:
dc.relation.ispartofJAMA Dermatology, 2015, vol. 151, num. 5, p. 544-548-
dc.rights(c) American Medical Association, 2015-
dc.subject.classificationCàncer de pell-
dc.subject.otherSkin cancer-
dc.titleMultiple BRAF Wild-Type Melanomas During Dabrafenib Treatment for Metastatic BRAF-Mutant Melanoma.-
Appears in Collections:Articles publicats en revistes (Fonaments Clínics)

Files in This Item:
File Description SizeFormat 
667493.pdf319.97 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.